Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

4SC AG. (2/26/13). "Press Release: 4SC Discovery and Leo Pharma Announce Exclusive Research and License Agreement for Inflammatory Skin Diseases". Planegg-Martinsried & Ballerup.

Organisations Organisation 4SC Discovery GmbH
  Today BioNtech Small Molecules GmbH
  Group BioNTech (Group)
  Organisation 2 Leo Pharma A/S
  Group Leo Pharma (Group)
Products Product drug discovery services
  Product 2 dermatic
Index term Index term Leo Pharma–4SC: drug discovery services, 201302– collab €1m upfront + €95m milestones + royalties r+d + commerc drugs for inflammatory skin diseases
Persons Person Kjøller, Kim (Leo Pharma 201201 SVP Global Development)
  Person 2 Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that its fully-owned research subsidiary 4SC Discovery GmbH has entered into an exclusive research and license agreement with pharmaceutical company LEO Pharma A/S, Ballerup, Denmark with the primary aim of jointly researching, developing and commercialising an oral treatment for inflammatory skin diseases such as psoriasis.

The collaboration has the potential to result in a novel and convenient breakthrough therapy for chronic skin conditions. The innovative compound, currently in the early development state, has already been proven in preclinical models to significantly reduce if not entirely eradicate symptoms of psoriasis.

Under the agreement, LEO Pharma will issue an upfront payment of EUR 1 million to 4SC Discovery and additional funding for research and development. LEO Pharma will receive an exclusive option to license the worldwide marketing and commercialisation rights of the compound for use in inflammatory skin diseases, including psoriasis and other therapeutic areas. Upon LEO Pharma exercising the option, 4SC Discovery will be eligible for a milestone payment of up to EUR 3 million and further payments upon achieving specific development milestones of up to EUR 92 million as well as up to double-digit royalties.

Improving quality of life

The deal marks the latest milestone in LEO Pharma's ambitious growth strategy, which involves actively seeking new opportunities to expand the company pipeline for the benefit of patients.

Kim Kjøller, Senior Vice President, Global Development, LEO Pharma, said: 'LEO Pharma is excited about the agreement with 4SC and the possibilities it offers patients. The compound has the potential to completely eradicate symptoms of psoriasis, liberating people from the burden of this chronic skin disease. LEO Pharma strives to constantly expand and improve treatment options for patients and this latest deal is the perfect example of our commitment to meeting patient needs with breakthrough novel therapies.'

New breakthrough therapy

For 4SC Discovery, the deal marks a key early-stage partnering deal with one of the company's compounds from its research.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'We are delighted to have won LEO Pharma, a global leader in skin diseases, as an ideal research and license partner for our highly innovative compound, which is based on the modulation of cytokines. Our goal is now to speed up and jointly develop a novel breakthrough therapy addressing the high medical need in chronic inflammatory skin diseases such as psoriasis. This partnership again demonstrates the great expertise and scientific potential of 4SC in the fields of autoimmune and inflammatory diseases.'

Dr. Ulrich Dauer, Chief Executive Officer of 4SC AG, adds: 'We are proud that our research subsidiary 4SC Discovery GmbH has entered into an early-stage partnering deal with such a renowned partner as LEO Pharma. This licensing partnership is another strong signal for the value generation potential of 4SC's research and another clear fulfilment of the promise we made to the capital markets a year ago when we started 4SC Discovery with the intention to focus on a stronger commercialisation of our early-stage research activities.'


About Leo Pharma A/S

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people's lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs. LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.

About 4SC Discovery GmbH and 4SC Group

4SC Discovery GmbH, a wholly-owned subsidiary of 4SC AG, specialises in the early-stage research and discovery of novel therapeutic compounds against cancer and autoimmune diseases. 4SC Discovery offers its technologies and research services to other companies and engages in partnerships with pharmaceutical and biotech companies to accelerate the development and commercialisation of its own early-stage therapeutic programmes. 4SC Group focuses on the discovery and clinical development of targeted small-molecule drugs for the treatment of cancer and autoimmune diseases in order to enhance patients' quality of life. At the end of 2012, 4SC Group had 86 employees. The company was founded in 1997 and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information on 4SC or 4SC Discovery please visit and or contact:

Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at), Tel.: +49-89-7007-63-66

MC Services
Raimund Gabriel, Mareike Mohr
raimund.gabriel(at), Tel.: +49-89-2102-2830
mareike.mohr(at), Tel.: +49-89-2102-2840

The Trout Group
Chad Rubin
Crubin(at), Tel.: +1-646-378-2947

For more information about LEO Pharma please visit or contact:

LEO Pharma A/S
Eva Juul Langlands, Corporate Communications Manager
eva.langlands(at), Tel.: +45-4188-3094

Record changed: 2017-04-02


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top